Surrozen, Inc.
SRZN
Rank in Stocks
#13682
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates... Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchsβ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-Γ, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Share Price
$31.61
Last synced: 2026-11-13
Market Cap
$372.18M
Change (1 day)
-0.19%
Change (1 year)
146.95%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Surrozen, Inc. (SRZN)
Category
Healthcare
EPS for Surrozen, Inc. (SRZN)
EPS as of September 2026 TTM: $-43.79
According to Surrozen, Inc.'s latest financial reports, its current EPS (TTM) is $-43.79. At the end of 2025 the company had an EPS of $-32.37, a decrease compared to its 2024 EPS of $-21.67.
EPS history for Surrozen, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-43.79 | 35.28% |
| 2025 | $-32.37 | 49.38% |
| 2024 | $-21.67 | 1.59% |
| 2023 | $-21.33 | 37.17% |
| 2022 | $-15.55 | -33.55% |
| 2021 | $-23.40 | -43.09% |
| 2020 | $-41.12 | -33.61% |
| 2019 | $-61.94 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | -97.97% |
US
|
|
| $15.66 | -135.76% |
US
|
|
| $-7.07 | -83.85% |
US
|
|
| $-5.29 | -87.92% |
AU
|
|
| $12.73 | -129.08% |
BE
|
Questions about Surrozen, Inc.'s earnings per share (EPS)
What is Surrozen, Inc.'s earnings per share (EPS)?
Surrozen, Inc.'s earnings per share (EPS) over the last twelve months is $-43.79, as of Sep 2026.
What was Surrozen, Inc.'s earnings per share (EPS) in 2025?
In 2025, Surrozen, Inc.'s earnings per share (EPS) was $-32.37, compared with $-21.67 in 2024.
How has Surrozen, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Surrozen, Inc.'s earnings per share (EPS) was highest in 2022 ($-15.55) and lowest in 2020 ($-41.12).
How does Surrozen, Inc.'s earnings per share (EPS) compare with similar companies?
Surrozen, Inc.'s earnings per share (EPS) ($-43.79) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.